Cosmo Pharmaceuticals N.V. Stock Forecast for 2023 - 2025 - 2030

Updated on 03/18/2024

Stock Rating
12
Price Target
CHF84.93
Consensus
Outperform
Upside
25.82%
Analysts
0
Stock Rating
12
Upside
25.82%
Analysts
0
Price Target
CHF84.93

Cosmo Pharmaceuticals N.V. Stock Forecast and Price Target

If the average price target of CHF84.93 set by distinguished experts for Cosmo Pharmaceuticals N.V. over the past few weeks is reached this year, there would be a potential upside of approximately 25.82% from the last closing price in March, 2024. This potential increase is based on a high estimate of CHF89.96 and a low estimate of CHF70.67. If you're looking for Cosmo Pharmaceuticals N.V. (COPN) stock information, you might also want to check out DURECT (NasdaqCM:DRRX).

CHF84.93

25.82% Upside

Buy
Buy

Cosmo Pharmaceuticals N.V. Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Cosmo Pharmaceuticals N.V.'s Price has grown, increasing from CHF0.00 to CHF0.00 – an increase of 100.00%. For next year, the 4 analysts predict Fair Value of CHF45.50, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof CHF238.84, which would mean a seven-year growth forecast of 100.00%.

2024 Fair Value Forecast
CHF45.50
2025 Fair Value Forecast
CHF102.53
2026 Fair Value Forecast
CHF135.31
2027 Fair Value Forecast
CHF190.16
2028 Fair Value Forecast
CHF326.86
2029 Fair Value Forecast
CHF323.09
2030 Fair Value Forecast
CHF238.84
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ARGX Stock Forecast argenx Outperform 4
359.20€ Buy/Sell 531.81€ 22.22%
GMAB Stock Forecast Genmab A/S Outperform 16
kr2.15k Buy/Sell kr2.71k 17.43%
REC Stock Forecast Recordati Industria Chimica e ... Hold 18
52.74€ Buy/Sell 48.61€ -5.76%
ZEAL Stock Forecast Zealand Pharma A/S Outperform 8
kr686.00 Buy/Sell kr357.00 15.16%
ORNBV Stock Forecast Orion Oyj Hold 14
35.99€ Buy/Sell 42.52€ 16.70%

Cosmo Pharmaceuticals N.V. Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Cosmo Pharmaceuticals N.V.'s Revenue has grown, increasing from CHF60.95M to CHF102.09M – an increase of 67.50%. For next year, the 4 analysts predict Revenue of CHF141.33M, which would mean an increase of 38.44%. Over the next seven years, the pros' prediction is Revenueof CHF394.00M, which would mean a seven-year growth forecast of 285.93%.

2024 Rev Forecast
CHF0.14B
2025 Rev Forecast
CHF0.22B
2026 Rev Forecast
CHF0.26B
2027 Rev Forecast
CHF0.34B
2028 Rev Forecast
CHF0.55B
2029 Rev Forecast
CHF0.54B
2030 Rev Forecast
CHF0.39B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£19.10 Buy/Sell £28.11 55.34%
ALKS Stock Forecast Alkermes Outperform 10
$28.60 Buy/Sell $33.27 18.88%
ALK B Stock Forecast ALK-Abelló A/S Outperform 13
kr129.70 Buy/Sell kr109.25 2.54%

Cosmo Pharmaceuticals N.V. Dividend per Share Forecast for 2023 - 2025 - 2030

Cosmo Pharmaceuticals N.V.'s Dividend per Share has increased by 10.53% In the last year, going from CHF0.95 to CHF1.05. According to 3 prominent analysts, Cosmo Pharmaceuticals N.V.'s Dividend per Share will fall by 19.05% in the next year, reaching CHF0.85. For the next seven years, the forecast is for Dividend per Share to grow by 116.19%.

2024 DPS Forecast
CHF0.85
2025 DPS Forecast
CHF0.97
2026 DPS Forecast
CHF1.13
2027 DPS Forecast
CHF1.97
2028 DPS Forecast
CHF1.84
2029 DPS Forecast
CHF2.04
2030 DPS Forecast
CHF2.27
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MOR Stock Forecast MorphoSys Outperform 6
65.52€ Buy/Sell 28.78€ 3.79%
EVT Stock Forecast Evotec Outperform 14
13.10€ Buy/Sell 37.33€ 90.84%
INDV Stock Forecast Indivior PLC Buy 14
£16.50 Buy/Sell £28.89 92.00%

Cosmo Pharmaceuticals N.V. Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
CHF0.05B
2025 FCF Forecast
CHF0.12B
2026 FCF Forecast
CHF0.26B
2027 FCF Forecast
CHF0.40B
2028 FCF Forecast
CHF0.38B
2029 FCF Forecast
CHF0.38B
2030 FCF Forecast
CHF0.29B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALM Stock Forecast Almirall Outperform 16
8.23€ Buy/Sell 11.39€ 39.73%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$32.43 Buy/Sell $41.00 24.88%
FAE Stock Forecast Faes Farma Hold 18
3.00€ Buy/Sell 3.90€ 21.67%

Cosmo Pharmaceuticals N.V. EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Cosmo Pharmaceuticals N.V.'s EBITDA has grown by 579.37%, from CHF6.06M to CHF41.17M. For the next year, analysts are expecting EBITDA to reach CHF67.11M – an increase of 63.01%. Over the next seven years, experts predict that EBITDA will grow by 519.38%.

2024 EBITDA Forecast
CHF0.07B
2025 EBITDA Forecast
CHF0.13B
2026 EBITDA Forecast
CHF0.16B
2027 EBITDA Forecast
CHF0.29B
2028 EBITDA Forecast
CHF0.36B
2029 EBITDA Forecast
CHF0.36B
2030 EBITDA Forecast
CHF0.26B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
PHM Stock Forecast Pharma Mar Outperform 13
30.62€ Buy/Sell 50.20€ 56.76%
BSLN Stock Forecast Basilea Pharmaceutica Outperform 6
CHF38.25 Buy/Sell CHF65.63 72.55%
DBV Stock Forecast DBV Technologies Outperform 5
1.43€ Buy/Sell 4.07€ 138.46%

Cosmo Pharmaceuticals N.V. EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Cosmo Pharmaceuticals N.V.'s EBIT has grown from CHF1.81M to CHF28.06M – a 1450.28% increase. Next year, analysts are expecting EBIT to reach CHF53.83M – an increase of 91.84%. Over the next seven years, the forecast is for EBIT to grow by 762.44%.

2024 EBIT Forecast
CHF0.05B
2025 EBIT Forecast
CHF0.12B
2026 EBIT Forecast
CHF0.15B
2027 EBIT Forecast
CHF0.21B
2028 EBIT Forecast
CHF0.35B
2029 EBIT Forecast
CHF0.35B
2030 EBIT Forecast
CHF0.24B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MOLN Stock Forecast Molecular Partners Outperform 4
CHF3.69 Buy/Sell CHF9.50 157.45%
ASRT Stock Forecast Assertio Holdings Buy 8
$0.93 Buy/Sell $3.50 276.34%
DRRX Stock Forecast DURECT Outperform 9
$1.01 Buy/Sell $6.75 568.32%

Cosmo Pharmaceuticals N.V. EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Cosmo Pharmaceuticals N.V.'s EPS has grown, increasing from CHF-0.55 to CHF0.00 – an increase of 100.00%. For next year, the 4 analysts predict EPS of CHF2.29, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof CHF12.02, which would mean a seven-year growth forecast of 100.00%.

2024 EPS Forecast
CHF2.29
2025 EPS Forecast
CHF5.16
2026 EPS Forecast
CHF6.81
2027 EPS Forecast
CHF9.57
2028 EPS Forecast
CHF16.45
2029 EPS Forecast
CHF16.26
2030 EPS Forecast
CHF12.02